A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has demonstrated proven efficacy in some hematologic cancers. We evaluated the safety and efficacy of LCAR-B38M, a dual epitope-binding CAR T cell therapy directed against 2 distinct B cell maturation antigen epitopes, in patients with relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wan-Hong, Liu, Jie, Wang, Bai-Yan, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Yang, Nan, Zhang, Ru, Zhang, Hui, Shen, Ying, Bai, Ju, Xu, Yan, Wang, Xu-Geng, Zhang, Rui-Li, Wei, Li-Li, Li, Zong-Fang, Li, Zhen-Zhen, Geng, Yan, He, Qian, Zhuang, Qiu-Chuan, Fan, Xiao-Hu, He, Ai-Li, Zhang, Wang-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302465/
https://www.ncbi.nlm.nih.gov/pubmed/30572922
http://dx.doi.org/10.1186/s13045-018-0681-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302465/
https://www.ncbi.nlm.nih.gov/pubmed/30572922
http://dx.doi.org/10.1186/s13045-018-0681-6

Ejemplares similares